The Ministry of Health (MS) announced that it will incorporate a drug into the SUS for the treatment of patients with mild and moderate cases of Covid-19.
The publication took place in the Official Gazette on Friday (6). MS has 180 days after publication of the incorporation to make the technology available on the public network.
The drug, composed of the antivirals nirmatrelvir and ritonavir, has the potential to reduce the progression of the disease to severe conditions and will be offered to immunocompromised adult patients aged 65 years or older.
The treatment can only be used in case of a positive test for Covid-19 and within five days after the onset of symptoms, according to information from the MS.
The folder stressed that the use is indicated for non-hospitalized patients, who are at high risk of complications and without the need for supplemental oxygen.
How it works
The MS explained that nirmatrelvir and ritonavir are two antiviral drugs used together for the treatment of Covid-19. According to the Ministry, the combination of compounds leads to a drug administered orally.
“Nirmatrelvir is an inhibitory molecule of an important SARS-CoV-2 enzyme. With this, the drug prevents the virus from proliferating, thus having a potent activity against the Covid-19 virus and other coronaviruses”, explained the folder.
“Ritonavir, in turn, inhibits the action of an enzyme that degrades nirmatrelvir. This helps nirmatrelvir to remain available in the bloodstream for a longer time, which enhances its action”, he concluded.
Source: CNN Brasil
